Skip to main content
Top

07-06-2018 | Rheumatoid arthritis | Article

Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study

Journal: Clinical Rheumatology

Authors: Ali Ismail A. Al-Gareeb, Faiq Isho Gorial, Ahmed S. Mahmood

Publisher: Springer London

Abstract

This study designed to identify the therapeutic efficacy of niclosamide (NCL) in Iraqi patients suffering from active rheumatoid arthritis (RA) who were using etanercept (ETN) for more than 3 months and still had high or moderate active RA. One hundred ten patients suffering from active rheumatoid arthritis (RA) who were using etanercept (ETN) for more than 3 months and still had high or moderate active RA were allocated randomly into two equal groups: one of them treated with 1000 mg/day NCL and the other treated with 1000 mg/day lactose in capsule dosage form. The study duration was 8 weeks. Clinical efficacy of the NCL was measured depending on scoring of the 28-joint Disease Activity Score (DAS28), simple disease activity index (SDAI), clinical disease activity index (CDAI), and Health Assessment Questionnaire Disability Index (HAQ-DI) at the baseline and at the end of the 8-week treatment period. Moreover, blood sample were taken from the patients at baseline and at after 8 weeks of treatment for measurement of the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), interleukin 1β (IL-1 β), interleukin-6, tumor necrosis factor (TNF-α), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. At the end of the clinical study, patients had good response to NCL when added to the ETN with a high significant improvement in the SJC, TJC, DAS-28, CDAI, SDAI, and HAQ-DI compared to patients who were received placebo drug. In addition to that, 33% of patients achieved an ACR 20% response (ACR20) on NCL and ETN. Of these, 4% achieved ACR50 and another 4% achieved ACR70 response. While those group treated by placebo + ETN, 5% achieved ACR20 response and no one reached to ACR50 or ACR70 response. Twenty-seven percent of RA patients who have taken the NCL achieved moderate EULAR score while only 17% from the group that taken placebo with ETN achieved moderate response. On the other hand, no significant reduction was found in CRP, ESR, TNF-α, and IL-6, while IL-1 β reduced significantly after treatment with NCL. Treatment with NCL also exerts a significant lowering in the serum level of the E-selectin, ICAM1, and VCAM1 when compared to their value in baseline level. In RA disease, the use of NCL as adjuvant with ETN has resulted in a marked reduction in clinical assessment scoring indices and significantly decreased the E-selectin, ICAM-1, and VCAM-1 with marked improvement in the quality of life of patients.
Literature
1.
Joshi VR (2012) Rheumatology, past present and future. J Assoc Physicians India 60:21–24PubMed
2.
Salaffi F, Ciapetti A (2013) Clinical disease activity assessments in rheumatoid arthritis. Int J Clin Rheumatol 8(3):347–360CrossRef
3.
Wasserman AM (2011) Diagnosis and Management of rheumatoid arthritis. Am Fam Physician 11:1245–1252
4.
Papagoras C, Voulgari PV, Drosos AA (2010) Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis. Autoimmun Rev 9:574–582CrossRefPubMed
5.
Detert J, Klaus P (2015) Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics 9:35–43PubMedPubMedCentral
6.
Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233(1):233–255CrossRefPubMedPubMedCentral
7.
Bustamante Marta F, Garcia-Carbonell R, Whisenant Katrijn D, Guma M (2017) Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 19:110CrossRefPubMedPubMedCentral
8.
Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, Combe B (2007) Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 66:358–363CrossRefPubMed
9.
Wei C, Mook RA Jr, Premont RT, Wang J (2018) Niclosamide: beyond an antihelminthic drug. Cell Signal 41:89–96CrossRef
10.
Huang M, Zeng S, Qiu Q, Xiao Y, Shi M, Zou Y, Yang X, Xu H, Liang L (2016) Niclosamide induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol 31:45–49CrossRefPubMed
11.
Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S, Shahrara S (2015) The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18:433–448CrossRefPubMedPubMedCentral
12.
Huang M, Qiu Q, Zeng S, Xiao Y, Shi M, Zou Y, Ye Y, Liang L, Yang X, Xu H (2015) Niclosamide inhibits the inflammatory and angiogenic activation of human umbilical vein endothelial cells. Inflamm Res 64:1023–1032CrossRefPubMed
13.
Arnett FC , Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–24
14.
Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K et al (2016) Clinical outcomes and biologic costs of switching between tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Adv Ther 33:1347–1359CrossRefPubMedPubMedCentral
15.
Van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L (2002) Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 5:R347–R351CrossRef
16.
Bello AE, Perkins EL, Jay R, Efthimiou P (2017) Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol 9:67–79CrossRefPubMedPubMedCentral
17.
Felson DT, LaValley MP (2014) The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing. Arthritis Res Ther 16:101CrossRefPubMedPubMedCentral
18.
Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O (2007) Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66:893–899CrossRefPubMedPubMedCentral
19.
Yongsong C, Oiling Y, Ke X, Jialin Z, Yuanbo L, Xiaoqing W et al (2016) Assessment of the therapeutic effect of total glucosides of peony for juvenile idiopathic arthritis: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2016:1–13
20.
Canhao H, Rodriguer AM, Gregorio MJ, Dias SS, Comes JA, Santos MJ et al (2018) Common evaluations of disease activity in rheumatoid arthritis reach discordant classifications across different populations. Frontiers in Medicine 5:1–8CrossRef
21.
Feng J, Chen Q, Yu F, Wang Z, Chen S, Jin Z, Cai Q, Liu Y, He J (2016) Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine (Baltimore) 95(8):e2859CrossRef
22.
Ai N, Wood RD, Yang E, Welsh WJ (2016) Niclosamide is a negative allosteric modulator of group I metabotropic glutamate receptors: implications for neuropathic pain. Pharm Res 33:3044–3056CrossRefPubMed
23.
Liang L, Huang M, Xiao Y, Zen S, Lao M, Zou Y, Shi M, Yang X (2015) Xu H. Inhibitory effects of niclosamide on inflammation and migration of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflamm Res 64:225–233CrossRefPubMed
24.
Tokuhira M, Hosaka S, Volin MV, Haines GK 3rd, Katschke KJ Jr, Kim S et al (2000) Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 43:1122–1133CrossRefPubMed
25.
Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J (2002) Soluble adhesion molecules (ICAM-1, VCAM-1 and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61:804–809CrossRefPubMedPubMedCentral
26.
Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ (1995) Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517–519CrossRefPubMed